TrialJournal for immunotherapy of cancer2022

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.

Charu Aggarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.